1
|
Feiner RC, Teschner J, Teschner KE, Radukic MT, Baumann T, Hagen S, Hannappel Y, Biere N, Anselmetti D, Arndt KM, Müller KM. rAAV Engineering for Capsid-Protein Enzyme Insertions and Mosaicism Reveals Resilience to Mutational, Structural and Thermal Perturbations. Int J Mol Sci 2019; 20:ijms20225702. [PMID: 31739438 PMCID: PMC6887778 DOI: 10.3390/ijms20225702] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Revised: 11/08/2019] [Accepted: 11/11/2019] [Indexed: 12/22/2022] Open
Abstract
Recombinant adeno-associated viruses (rAAV) provide outstanding options for customization and superior capabilities for gene therapy. To access their full potential, facile genetic manipulation is pivotal, including capsid loop modifications. Therefore, we assessed capsid tolerance to modifications of the structural VP proteins in terms of stability and plasticity. Flexible glycine-serine linkers of increasing sizes were, at the genetic level, introduced into the 587 loop region of the VP proteins of serotype 2, the best studied AAV representative. Analyses of biological function and thermal stability with respect to genome release of viral particles revealed structural plasticity. In addition, insertion of the 29 kDa enzyme β-lactamase into the loop region was tested with a complete or a mosaic modification setting. For the mosaic approach, investigation of VP2 trans expression revealed that a Kozak sequence was required to prevent leaky scanning. Surprisingly, even the full capsid modification with β-lactamase allowed for the assembly of capsids with a concomitant increase in size. Enzyme activity assays revealed lactamase functionality for both rAAV variants, which demonstrates the structural robustness of this platform technology.
Collapse
Affiliation(s)
- Rebecca C. Feiner
- Cellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615 Bielefeld, Germany; (R.C.F.); (J.T.); (K.E.T.); (M.T.R.)
| | - Julian Teschner
- Cellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615 Bielefeld, Germany; (R.C.F.); (J.T.); (K.E.T.); (M.T.R.)
| | - Kathrin E. Teschner
- Cellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615 Bielefeld, Germany; (R.C.F.); (J.T.); (K.E.T.); (M.T.R.)
| | - Marco T. Radukic
- Cellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615 Bielefeld, Germany; (R.C.F.); (J.T.); (K.E.T.); (M.T.R.)
| | - Tobias Baumann
- Biocatalysis group, Department of Chemistry, Technische Universität Berlin, 10623 Berlin, Germany;
| | | | - Yvonne Hannappel
- Physical and Biophysical Chemistry (PCIII), Department of Chemistry, Bielefeld University, 33615 Bielefeld, Germany;
| | - Niklas Biere
- Experimental Biophysics and Applied Nanoscience, Physics Department, Bielefeld University, 33615 Bielefeld, Germany; (N.B.); (D.A.)
| | - Dario Anselmetti
- Experimental Biophysics and Applied Nanoscience, Physics Department, Bielefeld University, 33615 Bielefeld, Germany; (N.B.); (D.A.)
| | - Katja M. Arndt
- Molecular Biotechnology, Institute for Biochemistry and Biology, University of Potsdam, 14476 Potsdam, Germany;
| | - Kristian M. Müller
- Cellular and Molecular Biotechnology, Faculty of Technology, Bielefeld University, 33615 Bielefeld, Germany; (R.C.F.); (J.T.); (K.E.T.); (M.T.R.)
- Correspondence: ; Tel.: +49-521-106-6323
| |
Collapse
|